Klimek, L. and Foerster-Ruhrmann, U. and Olze, H. and Beule, A. G. and Chaker, A. M. and Hagemann, J. and Huppertz, T. and Hoffmann, T. K. and Dazert, S. and Deitmer, T. and Strieth, S. and Wrede, H. and Schlenter, W. and Welkoborsky, H. J. and Wollenberg, B. and Becker, S. and Baerhold, F. and Klimek, F. and Casper, I. and Zuberbier, J. and Rudack, C. and Cuevas, M. and Hintschich, C. A. and Guntinas-Lichius, O. and Stoever, T. and Bergmann, C. and Werminghaus, P. and Pfaar, O. and Gosepath, J. and Groeger, M. and Beutner, C. and Laudien, M. and Weber, R. K. and Hildenbrand, T. and Hoffmann, A. S. and Bachert, C. (2023) Recommendations for reviewing the effectiveness and documentation of the course of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) in the German healthcare system. LARYNGO-RHINO-OTOLOGIE, 102 (02). pp. 89-99. ISSN 0935-8943, 1438-8685
Full text not available from this repository. (Request a copy)Abstract
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control. While national and international recommendations exist for the use of mepolizumab in CRSwNP, it has not yet been adequately specified how this therapy is to be monitored, what follow-up documentation is necessary, and when it should be terminated if necessary.Methods A literature search was performed to analyze previous data on the treatment of CRSwNP with mepolizumab and to determine the available evidence by searching Medline, Pubmed, the national and international trial and guideline registries and the Cochrane Library. Human studies published in the period up to and including 10/2022 were considered.Results Based on the international literature and previous experience by an expert panel, recommendations for follow-up, adherence to therapy intervals and possible therapy breaks, as well as termination of therapy when using mepolizumab for the indication CRSwNP in the German health care system are given on the basis of a documentation sheet.Conclusions Understanding the immunological basis of CRSwNP opens up new non-surgical therapeutic approaches with biologics for patients with severe, uncontrolled courses. Here, we provide recommendations for follow-up, adherence to therapy intervals, possible therapy pauses, or discontinuation of therapy when mepolizumab is used as add-on therapy with intranasal glucocorticosteroids to treat adult patients with severe CRSwNP that cannot be adequately controlled with systemic glucocorticosteroids and/or surgical intervention.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ENDOSCOPIC SINUS SURGERY; POSITION PAPER; ODOR IDENTIFICATION; NORMATIVE DATA; ASTHMA; PREVALENCE; PLACEBO; SAFETY; DISCRIMINATION; RECURRENCE; chronic rhinosinusitis; CRSwNP; biologicals; eosinophilic inflammation; mepolizumab |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 10:03 |
| Last Modified: | 30 Jan 2024 10:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60927 |
Actions (login required)
 |
View Item |
